𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma

✍ Scribed by Rupal S. Bhatt; Jaime Merchan; Robert Parker; Hua-Kang Wu; Liang Zhang; Virginia Seery; John V. Heymach; Michael B. Atkins; David McDermott; Vikas P. Sukhatme

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
139 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 clinical trial of nab-paclitax
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
✍ Evan M. Hersh; Steven J. O'Day; Antoni Ribas; Wolfram E. Samlowski; Michael S. G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Abstract ## BACKGROUND: __nab__‐Paclitaxel (ABI‐007, Abraxane), a 130‐nM, albumin‐bound (__nab__) particle form of Cremophor‐free paclitaxel, is approved for metastatic breast cancer. In the current study, the efficacy and safety of __nab__‐paclitaxel were evaluated in previously treated and ch

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer